PHILADELPHIA - A Pennsylvania federal judge on June 13 dismissed kickback claims from a qui tam False Claim Act (FCA) case in which a pharmaceutical company is accused of wrongfully marketing one of its prescription drugs, thereby causing the submission of false claims to the government under Medicare and Medicaid, but allowed off-label marketing claims to continue (United States of America, ex rel. Donald R. Galmines, et al. v. Novartis Pharmaceuticals Corp., No. 06-3213, E.D. Pa.; 2013 U.S. Dist. LEXIS 83100).